(Q38088215)

28 August 2017

title

First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments (English)

1 reference

28 August 2017

1 reference

3

1 reference

28 August 2017

Bin-Chi Liao

1

1 reference

28 August 2017

Chia-Chi Lin

series ordinal

2

1 reference

28 August 2017

publication date

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

357-369

1 reference

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0020-8

EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer

21 January 2018

1 reference

12 December 2020

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study

1 reference

12 December 2020

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

12 December 2020

First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study

1 reference

12 December 2020

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

12 December 2020

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

1 reference

12 December 2020

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

12 December 2020

10.1007/S40265-013-0020-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1048801714

0 references

1 reference